Danaher Corporation (DHR) reported third-quarter 2026 results on October 21 and raised its full-year adjusted earnings guidance. Adjusted diluted earnings per share reached $2.11, up from $1.89 a year earlier. Core sales grew 3.0% over the same period, according to the release filed as Exhibit 99.1 to a Form 8-K. The release credits better than expected revenue, earnings and cash flow in the quarter and improving trends across its end markets. The gap between those two growth rates is the main thing the quarter shows about the business.

Respiratory testing did most of the lifting

Danaher reported sales of $6.55 billion for the quarter, compared with $6.05 billion a year earlier. Core sales growth leaves out acquisitions, divestitures and currency effects, and it was 3.0%. Excluding respiratory testing, core growth was 5.5%. The 2.5 percentage point difference is the part of the quarter that depends on one product category. A reader who relies on the headline sales growth alone would see a broad gain. The segment figures show a narrower base, with one segment carrying a large share of the increase.

The Diagnostics segment shows where that difference sits. Its sales rose 17.0% in the quarter, but core growth was 0.5%. Excluding respiratory testing, Diagnostics core growth was 7.0%. Life Sciences and Biotechnology both grew core sales faster than the company total, at 4.5% and 5.0% respectively. Their reported growth rates were lower, at 4.0% and 0.5%, so the reported figures sit below the core figures for both segments.

Chart: third-quarter 2026 sales growth by segment, reported and core. Life Sciences grew 4.0% as reported and 4.5% on a core basis. Diagnostics grew 17.0% as reported and 0.5% on a core basis. Biotechnology grew 0.5% as reported and 5.0% on a core basis. The release uses the name Biotechnology for this segment, and this piece follows that name. View Danaher financial data

GAAP earnings grew faster than adjusted earnings

Adjusted diluted EPS was $2.11 against $1.89, a rise of 11.5% as stated in the release. GAAP diluted EPS from continuing operations was $1.71 against $1.27. As calculated by Trend & Ticker, the GAAP figure rose 34.6%, which is roughly three times the pace of the adjusted figure. Both measures came from the same quarter, so the difference reflects what the adjusted figure removes from the GAAP result.

The gap between the two per-share figures also narrowed. In the third quarter of 2025, GAAP EPS sat $0.62 below adjusted EPS. In the third quarter of 2026, the gap was $0.40, as calculated by Trend & Ticker. A smaller gap means the adjustments removed less per share from the GAAP result. The release figures this piece reads do not split that change between its causes, so this piece does not assign one.

Chart: diluted EPS in the third quarter, 2025 against 2026. Adjusted EPS moved from $1.89 to $2.11. GAAP EPS from continuing operations moved from $1.27 to $1.71. The distance between the two measures moved from $0.62 to $0.40, as calculated by Trend & Ticker. View Danaher financial data

Cash flow moved faster than earnings

Operating cash flow reached $1.89 billion in the quarter, compared with $1.66 billion a year earlier. Free cash flow, which is operating cash flow minus capital spending, came to $1.63 billion against $1.37 billion. The release labels free cash flow as a non-GAAP measure, so readers should treat it as a company-defined figure rather than a line item from the statement of cash flows.

As calculated by Trend & Ticker, free cash flow was 24.9% of sales in the third quarter of 2026, up from 22.6% a year earlier. Operating cash flow rose 13.5% over the same period, and free cash flow rose 19.1%. The faster rise in free cash flow means more of each sales dollar reached the cash line in the latest quarter than in the year-earlier quarter. Capital spending fell from $292 million to $255 million, according to the release. Part of the free cash flow gain therefore came from lower spending, not only from higher operating cash flow.

Chart: operating cash flow and free cash flow for the third quarter, 2025 against 2026, in billions of dollars. Operating cash flow moved from $1.66 billion to $1.89 billion. Free cash flow moved from $1.37 billion to $1.63 billion. Free cash flow as a share of sales moved from 22.6% to 24.9%, as calculated by Trend & Ticker. View Danaher financial data

Guidance rose by less than the quarter

Full-year adjusted EPS guidance is now $8.57 to $8.62. The prior range was $8.45 to $8.60. The midpoint moves from $8.53 to $8.60, as calculated by Trend & Ticker, a rise of about 0.8%. The new range starts above the old midpoint, so the low end of the outlook has moved higher, not only the top. The two figures cover different periods, so the comparison does not show that the quarter beat the company's own plan. It shows that the full-year range moved by a much smaller percentage than the quarter's earnings growth.

The release gives core sales growth guidance of approximately 2.5% for the full year. Excluding respiratory testing, it guides to mid-single-digit core growth. The release does not give a full-year revenue figure in dollars, so this piece uses growth rates only when it discusses the outlook.

The third quarter's core growth of 3.0% sits above the full-year core outlook of about 2.5%. For the fourth quarter alone, the release guides to core growth of about 3.0%, or 4.0% to 5.0% excluding respiratory testing. That puts the company's own fourth-quarter outlook in line with the third quarter's 3.0% pace.

Chart: the full-year 2026 outlook, before and after the update. Adjusted EPS guidance moved from $8.45 to $8.60 to $8.57 to $8.62. The midpoint moved from $8.53 to $8.60, as calculated by Trend & Ticker. Core sales growth guidance is approximately 2.5%. View Danaher financial data

The question the next report has to answer

The release leaves one question open. Diagnostics grew 7.0% in core terms once respiratory testing is excluded, but only 0.5% with it. Because the reported and core figures for Diagnostics sit so far apart, the total company growth rate is a weak guide to the underlying trend in that segment. The release puts the fourth-quarter drag from respiratory testing at about 150 basis points and ties it to influenza severity, which the company says it does not control.

The full-year guidance, which now sits at $8.57 to $8.62 in adjusted EPS, will be tested against the fourth-quarter result. The reader can check whether the company hits the upper or lower part of that range once the year closes.